期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

艾塞那肽治疗2型糖尿病安全性的系统评价 被引量：8

Safety of exenatide for type 2 diabetes: a systematic review
原文传递
导出
摘要 目的:系统评价艾塞那肽治疗2型糖尿病所致不良反应的发生情况。方法:计算机检索PubMed,EMBase,Cochrane,CNKI,VIP,CBM数据库,对纳入的随机对照试验(RCT)进行方法学质量评价,并用RevMan5.0软件进行Meta分析。结果:共纳入10个RCT,研究结果显示:艾塞那肽最主要的不良反应是胃肠道反应,恶心发生的概率最大,均高于安慰剂组和胰岛素组,但反应均较轻微,绝大多数患者可以耐受。结论:艾塞那肽不良反应较轻微,因此可以用来治疗口服降糖药不能有效控制血糖的2型糖尿病患者,但因纳入研究随访时间较短,其长期安全性还需进一步验证。 OBJECTIVE To assess the safqty of exenatide in the treatment of type 2 diabetic patients. METHODS The Cochranc Library, PubMed, EMBase, CBM, VIP and CNKI databases were searched. Randomized controlled trails （RCTs） that included were evaluated and analyzed by the software RevMan 5.0. RESULTS Ten studies were included. Most of the adverse events reported were mild to moderate in intensity. The result of Meta analysis demonstrated that gastrointestinal events occurred more commonly in patients receiving exenatide than those receiving placebo and insulin. CONCLUSION The study suggests that exenatide is safe for type 2 diabetes, but it also need further studies to provide more sufficient evidence for the longterm safety of exenatide.
作者 占美 吴逢波 吴斌 柳汝明 唐尧
机构地区 四川大学华西医院药剂科
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2011年第6期473-477,共5页 Chinese Journal of Hospital Pharmacy
关键词 艾塞那肽 糖尿病 安全性 系统评价 META分析 exenatide diabetes mellitus safety systematic review meta-analysis
分类号 R977 [医药卫生—药品]
  • 相关文献

参考文献14

  • 1S. Hernández-Díaz,H.-O. Adami.Diabetes therapy and cancer risk: causal effects and other plausible explanations[J]. Diabetologia . 2010 (5)
  • 2DeFronzo RA.PharmaPologiP therapy for type2diabetesmellitus. Annals of Internal Medicine . 1999
  • 3Cochrane Handbook for Sys-tematic Reviews of Interventions Version5.0.2[updated Sep-tember2009]. . 2009
  • 4Barnett AH,,Burger J,Johns D,et al.Tolerability and effica-cy of exenatide and titrated insulin glargine in adult patientswith type2diabetes previously uncontrolled with metformin ora sulfonylurea:A multinational,randomized,open-label,two-period,crossover noninferiority trial. Clinical Therapeutics . 2007
  • 5Davies MJ,Donnelly R,Barnett AH,et al.Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type2diabetes:results of the Helping Evaluate Exenatide in pa-tients with diabetes compared with Long-Acting insulin(HEELA)study. Diabetes Obesity and Metabolism . 2009
  • 6Gao Y,Yoon KH,Chuang LM,et al.Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Research and Clinical Practice . 2009
  • 7Bunck MC,Diamant M,Corner A,et al.One-year treatment with exenatide improves beta-cell function,compared with insulin glargine, in metformin-treated type 2 diabetic patients:a randomized,controlled trial. Diabetes Care . 2009
  • 8Davis SN,Xu H,Johns D,et al.Exploring the substitu-tion of exenatide for insulin in patients with type2diabe-tes treated with insulin in combination with oral antidia-betic agents. Diabetes Care . 2007
  • 9ZINMAN B,HOOGWERF B J,DURAN G S,et al.The effectof adding Exenatide to a thiazolidinedione in suboptimallycontrolled type 2 diabetes:a randomized trial. Annal of International Medicine . 2007
  • 10Heine RJ,Van Gaal LF,Johns D,Mihm MJ,Widel MH,Brodows RG.Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine . 2005

同被引文献98

  • 1李显丽,李奕平,王晓苓.艾塞那肽治疗肥胖2型糖尿病的临床疗效观察[J].昆明医科大学学报,2012,33(4):125-127. 被引量：4
  • 2Blonde L,Klein E,Han J. Interim analysis of the effects of exenatide treatment on A1C,weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes[J].Diabetes,Obesity and Metabolism,2006,(04):436-447.
  • 3Best JH,Hoogwerf BJ,Herman WH. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies:a retrospective analysis of the LifeLink database[J].Diabetes Care,2011,(01):90-95.
  • 4Klonoff DC,Buss JB,Nielsen LL. Exenatide effects on diabetes,obesity,cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years[J].Current Medical Research and Opinion,2008,(01):275-286.
  • 5Drucker DJ,Buse JB,Taylor K. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes:a randomised,open-label,non-inferiority study[J].The Lancet,2008,(9645):1240-1250.doi:10.1016/S0140-6736(08)61206-4.
  • 6Ligumsky H,Wolf I,Israeli S. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells[J].Breast Cancer Research and Treatment,2012,(02):449-461.
  • 7Nguyen HN,Wey SP,Juang JH. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo[J].Biomaterials,2011,(10):2673-2682.
  • 8Yang HJ;Park IS;Na K.Biocompatible microspheres based on acetylated polysaccharide prepared from water-in-oil-in water(W1/O/W2) double-emulsion method for delivery of type ?域 diabetic drug(exenatide)[J],Colloids and Surfaces A:Physicochemical and Engineering Aspects,2009,(01):115-120.
  • 9Davis SN,Johns D,Maggs D. Exploring the substitution of extenatide for insulin in patients with type 2 diaberes treated with insulin in combination with oral antidabetes agents[J].Diabetes Care,2007,(11):2767-2772.doi:10.2337/dc06-2532.
  • 10Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and centralnervous system[J]. Endocrinology,2004,145 (6) :2653- 2659.

引证文献8

二级引证文献47

中国医院药学杂志
2011年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部